We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.06B
AUM Growth
-$215M
Cap. Flow
-$288M
Cap. Flow %
-5.68%
Top 10 Hldgs %
52.55%
Holding
152
New
45
Increased
20
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$94.3M
2
PFE icon
Pfizer
PFE
+$87.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$79.4M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$38.7M
5
INSM icon
Insmed
INSM
+$35M

Top Sells

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$121M
2
ACH
Accendra Health
ACH
+$64.2M
3
ALHC icon
Alignment Healthcare
ALHC
+$40.8M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$38.8M
5
BCAX
Bicara Therapeutics
BCAX
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.22%
2 Real Estate 0.01%
3 Technology 0.01%
4 Consumer Discretionary 0.01%
5 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CON
51
Concentra Group Holdings
CON
$4.18B
$14.1M 0.28%
650,000
– –
MTSR
52
DELISTED
Metsera Inc
MTSR
$13.6M 0.27%
+500,000
New +$14.2M
DCGO icon
53
DocGo
DCGO
$62.4M
$13.3M 0.26%
5,051,500
-2,144,456
-30% -$8.6M
TXG icon
54
10x Genomics
TXG
$5.97B
$13.1M 0.26%
1,503,594
+6,594
+0.4% +$83.1K
LUNG icon
55
Pulmonx
LUNG
$52.8M
$12.7M 0.25%
1,890,000
+355,237
+23% +$2.52M
BBNX
56
Beta Bionics
BBNX
$704M
$12.4M 0.25%
+1,016,000
New +$18.9M
ZBIO
57
Zenas BioPharma
ZBIO
$2.04B
$12.3M 0.24%
1,562,942
– –
FHTX icon
58
Foghorn Therapeutics
FHTX
$301M
$11.9M 0.23%
3,255,514
– –
NVCR icon
59
NovoCure
NVCR
$1.89B
$11.6M 0.23%
+650,119
New +$14.8M
OPK icon
60
Opko Health
OPK
$1.25B
$11.5M 0.23%
+6,906,362
New +$11.4M
DCTH icon
61
Delcath Systems
DCTH
$399M
$10.4M 0.2%
+813,106
New +$11.5M
GHRS icon
62
GH Research
GHRS
$1.92B
$10.2M 0.2%
+925,000
New +$10.3M
RXST icon
63
RxSight
RXST
$250M
$9.91M 0.2%
+392,332
New +$11.7M
SLP icon
64
Simulations Plus
SLP
$371M
$8.68M 0.17%
+354,089
New +$10.7M
DYN icon
65
Dyne Therapeutics
DYN
$4.28B
$8.5M 0.17%
812,408
+376,755
+86% +$5.39M
PCVX icon
66
Vaxcyte
PCVX
$7.88B
$8.5M 0.17%
225,000
– –
SION
67
Sionna Therapeutics
SION
$2.1B
$7.81M 0.15%
+747,000
New +$12.2M
SYRE icon
68
Spyre Therapeutics
SYRE
$8.68B
$7.26M 0.14%
450,000
– –
GPCR icon
69
Structure Therapeutics
GPCR
$3.4B
$6.46M 0.13%
373,407
– –
NPCE icon
70
Neuropace
NPCE
$522M
$6.14M 0.12%
+500,000
New +$6.26M
CATX icon
71
Perspective Therapeutics
CATX
$327M
$6.03M 0.12%
2,829,413
-109,341
-4% -$328K
NGNE icon
72
Neurogene
NGNE
$663M
$5.23M 0.1%
446,880
-1,265
-0.3% -$22K
TOI icon
73
The Oncology Institute
TOI
$495M
$3.83M 0.08%
3,360,052
– –
HLVX
74
DELISTED
HilleVax
HLVX
$2.73M 0.05%
1,882,654
– –
CALC icon
75
CalciMedica
CALC
$11.3M
$2.48M 0.05%
1,300,000
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2025 Portfolio in Review

As of Q1 2025, Deerfield Management held 152 positions worth $5.06B, down 4.1% from $5.28B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deerfield Management withdrew a net $288M in Q1 2025, closing 29 positions and reducing 17 holdings. Its most notable exit was Waystar Holding Corp, an estimated $121M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate and Technology.

Against the trend, Deerfield Management opened a new position in United Therapeutics worth $84.8M.

  • Deerfield Management's largest Q1 2025 buy was United Therapeutics: 275,226 shares worth $84.8M.
  • Deerfield Management added most to Neurocrine Biosciences in Q1 2025, an estimated $79.4M increase.
  • Deerfield Management's biggest Q1 2025 reduction was Alignment Healthcare, cutting an estimated $40.8M.
  • Deerfield Management fully exited Waystar Holding Corp in Q1 2025, selling an estimated $121M.
  • Deerfield Management's ten largest holdings make up 53% of its $5.06B portfolio in Q1 2025.
  • Deerfield Management opened 45 new positions and closed 29 in Q1 2025.
  • Deerfield Management's portfolio value fell 4.1% quarter-over-quarter to $5.06B.

Based on Deerfield Management's 13F filing for Q1 2025, filed 15 May 2025.